Informations générales (source: ClinicalTrials.gov)
A European, Multicenter, Randomized, Open-label, Phase II Trial Aiming to Assess the Clinical and Biological Activity of an Anti-PD-L1 (Atezolizumab) in Operable Localised Soft Tissue Sarcomas Patients to be Treated With Radiotherapy
Interventional
Phase 2
Centre Leon Berard (Voir sur ClinicalTrials)
août 2018
août 2024
26 août 2025
This multicentric, randomised, Phase II trial will use a pick-the-winner design in order
to evaluate the clinical and biological activity of atezolizumab when combined with
pre-operative or post-operative radiotherapy in STS patients.
Following Inform Consent Form (ICF) signature, eligible patients will be randomised
(1:1:1) to receive:
- Arm A: Radiotherapy followed by atezolizumab then surgery.
- Arm B: Atezolizumab followed by surgery then radiotherapy.
- Arm C: Radiotherapy then surgery followed by atezolizumab.
The sequence of the study treatments is different among the 3 study arms. However, the
dose regimens will be the same:
- Atezolizumab will be administered to all patients at the dose of 1200mg, by IV
injection, for 2 cycles (Q3W).
- Radiotherapy will be administered to all patients at the dose of 2Gy/day, 5 days per
week, for a total of 5 weeks and 50Gy.
- Surgery will be performed as per institutional practice.
Randomisation will be stratified according to histological subtypes as follows:
Group 1: Liposarcoma (LPS), Undifferentiated Pleomorphic Sarcoma (UPS), Leiomyosarcoma
(LMS), myxofibrosarcoma, angiosarcoma versus Group 2: all translocation sarcoma except
Ewing, rhabdomyosarcoma (RMS) and myxoid LPS.
Etablissements
| Les établissements d'Île-de-France dont les données sont issues de ClinicalTrials.gov Origine et niveau de fiabilité des données | |||||
|---|---|---|---|---|---|
| CLCC INSTITUT GUSTAVE ROUSSY | Charles HONORE, MD | Contact (sur clinicalTrials) | |||
| Les établissements sans correspondance certaine dans le répertoire FINESS dont les données sont issues de ClinicalTrials.gov Origine et niveau de fiabilité des données | |||||
| Centre Léon Bérard - 69008 - Lyon - France | Jean-Yves BLAY, MD | Contact (sur clinicalTrials) | |||
| Centre Oscar Lambret - Lille - France | Nicolas PENEL, MD | Contact (sur clinicalTrials) | |||
| Institut Bergonie - Bordeaux - France | ITALIANO Antoine, MD | Contact (sur clinicalTrials) | |||
| Institut Claudius Regaud - 31059 - Toulouse - France | Thibaud VALENTIN, MD | Contact (sur clinicalTrials) | |||
Critères
Tous
Inclusion Criteria:
1. Male or female patients aged ≥ 18 years at time of inform consent signature.
2. Histologically confirmed soft tissue sarcoma including liposarcoma, leiomyosarcoma,
myxofibrosarcoma, UPS, angiosarcoma, all translocation sarcoma except Ewing,
rhabdomyosarcoma (RMS), and myxoid liposarcoma (LPS).
3. Soft tissue sarcoma suitable for neoadjuvant RT and amenable to surgery with
curative intent (high-grade non-metastatic tumors, intermediate and low-grade tumors
greater than 5 cm).
Note: Patients with local relapsing disease amenable to surgery are eligible.
4. Presence of at least one tumor lesion with a diameter ≥10 mm, visible by medical
imaging and accessible to percutaneous or endoscopic sampling that permit core
needle biopsy without unacceptable risk and suitable for retrieval of a minimum of
three, but ideally 4, cores using a biopsy needle of at least 16-gauge.
5. Eastern Cooperative Oncology Group performance status (ECOG PS) of 0 or 1 (Appendix
4).
6. Adequate end organs and bone marrow functions as defined below according to lab
tests performed within 7 days before W1D1:
- Bone marrow (without transfusion within 2 weeks before W1D1):
- Hemoglobin ≥ 9.0 g/dL,
- Absolute neutrophil count ≥ 1.5 x 109/L,
- Platelets ≥ 100 x 109/L,
- Lymphocyte count ≥ 0.5 x 109/L.
- Renal function:
- Serum creatinine clearance ≥ 30 mL/min/1.73m2 (MDRD or CKD-EPI formula -
Appendix 3)
- Hepatic function
- Serum bilirubin < 1.5 × Upper Limit of Normal (ULN), with the following
exception: Patients with known Gilbert disease who have serum bilirubin
level ≤ 3 ULN may be enrolled.
- Aspartate aminotransferase (AST), alanine aminotransferase (ALT) and
alkaline phosphatase ≤ 2.5 ULN.
- Coagulation
- INR and aPTT ≤ 1.5 ULN Note: This is applicable only for patients not
receiving an anticoagulant treatment: patients receiving therapeutic
anticoagulation must be on stable dose.
7. Minimal wash-out period for prior treatments (minimal time required from the end
date of prior treatment to W1D1):
- Immunosuppressive medication > 28 days, with the exceptions of intranasal and
inhaled corticosteroids or systemic corticosteroids at physiological doses,
which are not to exceed 10 mg/day of prednisone, or an equivalent
corticosteroid,
- Live attenuated vaccines > 30 days, Note: Seasonal influenza vaccines for
injection are generally inactivated flu vaccines and are allowed; however
intranasal influenza vaccines (e.g., Flu-Mist®) are live attenuated vaccines,
and are not allowed.
- Major surgical procedure, open biopsy (excluding skin cancer resection and
screening tumor biopsy), or significant traumatic injury > 14 days (the wound
must have healed),
- Any approved or investigational anti-cancer therapy, including chemotherapy,
hormonal therapy or targeted therapy > 21 days,
- Systemic immunostimulatory agents > 28 days or five half-lives of the drug,
whichever is longer,
- Oral or IV antibiotics > 14 days.
8. Women of child-bearing potential must have a negative serum pregnancy test within 7
days before randomisation and must agree to use an effective form of contraception
from the time of the negative pregnancy test up to 5 months after the last dose of
atezolizumab (See Appendix 5).
9. Fertile men must agree to use an effective method of birth control during the study
and for up to 5 months after the last dose of atezolizumab.
10. Patient should understand, sign, and date the written voluntary informed consent
form prior to any protocol-specific procedures performed. Patient should be able and
willing to comply with study visits and procedures as per protocol.
11. Patients must be covered by a medical insurance in country where applicable.
1. Male or female patients aged ≥ 18 years at time of inform consent signature.
2. Histologically confirmed soft tissue sarcoma including liposarcoma, leiomyosarcoma,
myxofibrosarcoma, UPS, angiosarcoma, all translocation sarcoma except Ewing,
rhabdomyosarcoma (RMS), and myxoid liposarcoma (LPS).
3. Soft tissue sarcoma suitable for neoadjuvant RT and amenable to surgery with
curative intent (high-grade non-metastatic tumors, intermediate and low-grade tumors
greater than 5 cm).
Note: Patients with local relapsing disease amenable to surgery are eligible.
4. Presence of at least one tumor lesion with a diameter ≥10 mm, visible by medical
imaging and accessible to percutaneous or endoscopic sampling that permit core
needle biopsy without unacceptable risk and suitable for retrieval of a minimum of
three, but ideally 4, cores using a biopsy needle of at least 16-gauge.
5. Eastern Cooperative Oncology Group performance status (ECOG PS) of 0 or 1 (Appendix
4).
6. Adequate end organs and bone marrow functions as defined below according to lab
tests performed within 7 days before W1D1:
- Bone marrow (without transfusion within 2 weeks before W1D1):
- Hemoglobin ≥ 9.0 g/dL,
- Absolute neutrophil count ≥ 1.5 x 109/L,
- Platelets ≥ 100 x 109/L,
- Lymphocyte count ≥ 0.5 x 109/L.
- Renal function:
- Serum creatinine clearance ≥ 30 mL/min/1.73m2 (MDRD or CKD-EPI formula -
Appendix 3)
- Hepatic function
- Serum bilirubin < 1.5 × Upper Limit of Normal (ULN), with the following
exception: Patients with known Gilbert disease who have serum bilirubin
level ≤ 3 ULN may be enrolled.
- Aspartate aminotransferase (AST), alanine aminotransferase (ALT) and
alkaline phosphatase ≤ 2.5 ULN.
- Coagulation
- INR and aPTT ≤ 1.5 ULN Note: This is applicable only for patients not
receiving an anticoagulant treatment: patients receiving therapeutic
anticoagulation must be on stable dose.
7. Minimal wash-out period for prior treatments (minimal time required from the end
date of prior treatment to W1D1):
- Immunosuppressive medication > 28 days, with the exceptions of intranasal and
inhaled corticosteroids or systemic corticosteroids at physiological doses,
which are not to exceed 10 mg/day of prednisone, or an equivalent
corticosteroid,
- Live attenuated vaccines > 30 days, Note: Seasonal influenza vaccines for
injection are generally inactivated flu vaccines and are allowed; however
intranasal influenza vaccines (e.g., Flu-Mist®) are live attenuated vaccines,
and are not allowed.
- Major surgical procedure, open biopsy (excluding skin cancer resection and
screening tumor biopsy), or significant traumatic injury > 14 days (the wound
must have healed),
- Any approved or investigational anti-cancer therapy, including chemotherapy,
hormonal therapy or targeted therapy > 21 days,
- Systemic immunostimulatory agents > 28 days or five half-lives of the drug,
whichever is longer,
- Oral or IV antibiotics > 14 days.
8. Women of child-bearing potential must have a negative serum pregnancy test within 7
days before randomisation and must agree to use an effective form of contraception
from the time of the negative pregnancy test up to 5 months after the last dose of
atezolizumab (See Appendix 5).
9. Fertile men must agree to use an effective method of birth control during the study
and for up to 5 months after the last dose of atezolizumab.
10. Patient should understand, sign, and date the written voluntary informed consent
form prior to any protocol-specific procedures performed. Patient should be able and
willing to comply with study visits and procedures as per protocol.
11. Patients must be covered by a medical insurance in country where applicable.
1. Patients with evidence of metastatic disease, defined by the presence of any of the
followings:
- Lesions that are discontinuous from the primary tumor,
- Lesions that are not regional lymph nodes,
- Lesions that do not share a body cavity with the primary tumor,
- Evidence by medical imagining (eg CT-scan) of metastatic disease.
2. Patients with history of severe allergic or other hypersensitivity reactions to:
- Chimeric or humanized antibodies or fusion proteins,
- Biopharmaceuticals produced in Chinese hamster ovary cells, or
- Any component of the atezolizumab formulation.
3. Patients using or requirement to use while on the study of any not permitted
concomitant medications :
- Any approved anti-cancer systemic treatment including chemotherapy,
hormonotherapy, biological therapy, immunotherapy other than atezolizumab,
- Any investigational agents,
- Live vaccines. Examples of live vaccines include, but are not limited to, the
following: measles, mumps, rubella, chicken pox, yellow fever, rabies, BCG, and
typhoid (oral) vaccine. Seasonal influenza vaccines for injection are generally
killed virus vaccines and are allowed; however intranasal influenza vaccines
(e.g. Flu-Mist®) are live attenuated vaccines, and are not allowed during the
study active period,
- Traditional herbal medicines since the ingredients of many herbal medicines are
not fully studied and their use may result in unanticipated drug-drug
interactions that may cause or confound assessment of toxicity,
- Immunostimulatory agents, including but not limited to IFN-α, IFN-γ, or IL-2,
during the entire study. These agents, in combination with atezolizumab, could
potentially increase the risk for autoimmune conditions. In addition, all
patients (including those who discontinue the study early) should not receive
other immunostimulatory agents for 10 weeks after the last dose of
atezolizumab,
- Immunosuppressive medications, including but not limited to cyclophosphamide,
azathioprine, methotrexate, and thalidomide. These agents could potentially
alter the activity and the safety of atezolizumab. Systemic corticosteroids and
anti-TNF-α agents may attenuate potential beneficial immunologic effects of
treatment with atezolizumab but may be administered to manage irAE (See Safety
Plan). If feasible, alternatives to these agents should be considered.
4. Patients with a malignancy other than STS within 5 years prior to randomisation with
the exception of those with a negligible risk of metastasis or death and treated
with expected curative outcome (such as adequately treated in situ carcinoma of the
cervix, basal or squamous cell skin cancer, localised prostate cancer or ductal in
situ carcinoma treated surgically with curative intent).
5. Patients with severe infections within 4 weeks prior to randomisation including but
not limited to hospitalization for complications of infection, bacteraemia, or
severe pneumonia.
6. Patients with history of autoimmune disease including but not limited to myasthenia
gravis, myositis, autoimmune hepatitis, systemic lupus erythematosus, rheumatoid
arthritis, inflammatory bowel disease, vascular thrombosis associated with
antiphospholipid syndrome, Wegener's granulomatosis, Sjögren's syndrome,
Guillain-Barré syndrome, multiple sclerosis, vasculitis, or glomerulonephritis.
Note: Patients with eczema, psoriasis, lichen simplex chronicus, or vitiligo with
dermatologic manifestations only (e.g., patients with psoriatic arthritis would be
excluded) are permitted provided that they meet the following conditions:
- Rash must cover less than 10% of body surface area (BSA).
- Disease is well controlled at baseline and only requiring low potency topical
steroids.
- No acute exacerbations of underlying condition within the previous 12 months
(not requiring PUVA [psoralen plus ultraviolet A radiation], methotrexate,
retinoids, biologic agents, oral calcineurin inhibitors, high-potency or oral
steroids)" Note: Patients with a history of autoimmune hypothyroidism on a
stable dose of thyroid replacement hormone may be eligible.
Note: Patients with a type I diabetes well controlled by a stable dose of insulin
are eligible.
7. Patients with active B or C hepatitis infection. Note: Patients with past Hepatitis
B Virus (HBV) infection or resolved HBV infection (defined as having a negative
HBsAg test and a positive antibody to hepatitis B core antigen [anti-HBc] antibody
test) are eligible. Patients positive for Hepatitis C Virus (HCV) antibody are
eligible only if polymerase chain reaction (PCR) is negative for HCV RNA.
8. Patients with active tuberculosis.
9. Patients with ongoing toxicities (Grade ≥1 according to CTCAE V5.0) from previous
therapies, except for alopecia (any grades) and lab values defined in inclusion
criteria.
Note: Some Grade 2 may be permitted following discussion with the Sponsor.
10. Patients with evidence of significant uncontrolled concomitant disease that could
affect compliance with the protocol or interpretation of results, including
significant liver disease (such as cirrhosis, uncontrolled major seizure disorder,
or superior vena cava syndrome).
11. Patients with significant cardiovascular disease, such as New York Heart Association
cardiac disease Class II or greater, myocardial infarction within 3 months prior to
W1D1, unstable arrhythmias or unstable angina.
Notes:
- Patients with a known Left Ventricular Ejection Fraction (LVEF) < 40% will be
excluded
- Patients with known coronary artery disease, congestive heart failure not
meeting the above criteria, or LVEF < 50% must be on a stable medical regimen
that is optimized in the opinion of the treating physician, in consultation
with a cardiologist if appropriate.
12. Patients with history of idiopathic pulmonary fibrosis (including pneumonitis),
drug-induced pneumonitis, organizing pneumonia (i.e. bronchiolitis obliterans,
cryptogenic organizing pneumonia), or evidence of active pneumonitis on imaging.
13. Pregnant or lactating women.
14. Prior organ transplantation including allogeneic stem cell transplantation.
15. Patients who are known to be serologically positive for human immunodeficiency virus
(HIV).
E16. Patient with prior treatment with anti-PD-1, or anti-PD-L1 immune checkpoint
blockade therapies.